title: Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis.
abstract: Psoriasis is a chronic immune-mediated inflammatory condition that affects 2-3% of the population. Apremilast was FDA-approved in March 2014 for the treatment of psoriatic arthritis and in September 2014 for the treatment of moderate to severe plaque psoriasis. Apremilast appears to have lower efficacy than some biologic agents such as adalimumab and ustekinumab, which achieve a PASI-75 in approximately 70% of patients after 12-16 weeks of therapy. However, its ease of administration as an oral agent coupled with a mild side effect profile make it an attractive option for psoriasis treatment. Herein, we present a patient with a 17-year history of plaque type psoriasis recalcitrant to topical, oral, and biologic mediations who attained near-complete remission after therapy with a combination of adalimumab and apremilast.
authors.affiliation: University of California, San Francisco, San Francisco.
authors.forename: Melissa J
authors.initials: MJ
authors.lastname: Danesh
authors.forename: Kourosh
authors.initials: K
authors.lastname: Beroukhim
authors.forename: Catherine
authors.initials: C
authors.lastname: Nguyen
authors.forename: Ethan
authors.initials: E
authors.lastname: Levin
authors.forename: John
authors.initials: J
authors.lastname: Koo
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use*; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*; D019233:Retreatment; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D013792:Thalidomide; D000068879:Adalimumab; C505730:apremilast